TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03570619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy.
Study: NCT01672775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16C3F
Description: intravenous (IV) infusion
Study: NCT03248739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Bactiseal 'large' catheter (EVD)
Description: Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
Study: NCT03570619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.~Patients in arm Metastatic CRPC will receive therapy with monotherapy nivolumab therapy at flat dose 480 mg IV every 4 weeks for up to 104 weeks of total therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients in arms Metastatic CRPC and Experimental: Solid Tumors (non-prostate) will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 104 weeks of total therapy.
Study: NCT05022940

Intervention type: OTHER
Intervention: Usual gold-standard multidisciplinary rehabilitation for TBI
Description: In individual and group interventions within a holistic interdisciplinary rehabilitation program focusing on resumption of daily activities and social roles. Interventions could include physiotherapy or physical training, occupational therapy, speech therapy, and neuropsychology/psychology, which aimed at reducing the impacts of cognitive difficulties in daily life by using self-guided and environmental strategies.
Study: NCT02826486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: BL-8040 subcutaneous (SC) injections
Study: NCT00473512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
Study: NCT02826486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Description: BL-8040 subcutaneous (SC) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as a 30-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as a 30-minute IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: • IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
Study: NCT00789945

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Arm B
Description: Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor.
Study: NCT02293512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training
Description: A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
Study: NCT01013272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 0.5mg orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 100mg orally, daily
Study: NCT02309476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, Green Laser 0.75
Description: Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, Green Laser 1
Description: Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
Study: NCT00473512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate MTD
Description: Abiraterone acetate MTD orally for 12 cycles (28 day each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
Study: NCT02309476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, 70% Yellow Laser 0.75
Description: Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, 70% Yellow Laser 1
Description: Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid
Study: NCT03248739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orange Bactiseal 'small' catheter (EVD)
Description: Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
Study: NCT02309476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, 40% Yellow Laser 0.75
Description: Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PASCAL Laser, 40% Yellow Laser 1
Description: Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid
Study: NCT04553757

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT00159211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UMULINE NPH
Description: UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
Study: NCT04789421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical, dermoscopy and Reflective confocal microscopy evaluations
Description: Adjunctive reflective confocal microscopy to dermoscopy and clinical dermatological evaluation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Clinical, dermoscopy evaluations
Description: Dermoscopy and clinical dermatological evaluation only
Study: NCT00293735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol (seizure prevention)
Description: 20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4 (seizure prevention)
Description: 4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
Study: NCT03001648

Intervention type: PROCEDURE
Intervention: PGS (Preimplantation Genetic Screening) with trophectoderm biopsy
Description: PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
Study: NCT05130658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality treadmill training
Description: C-Mill (Motekforce Link, Amsterdam, The Netherlands) is an instrumented treadmill that uses visual (on the screen as well on the treadmill) and acoustic cues for gait and balance training. The C-Mill allows for gait and balance adaptability strategy as it can provide obstacle avoidance environments, change in speed and various walking pathways in a safe and controlled environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: Conventional gait and balance training using treadmill.
Study: NCT01277965

Intervention type: OTHER
Group type: OTHER
Intervention: 50%VO2maxTBR50
Description: The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%

Intervention type: OTHER
Group type: OTHER
Intervention: 50%VO2max TBR80
Description: The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%

Intervention type: OTHER
Group type: OTHER
Intervention: 75%VO2max TBR80
Description: The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%

Intervention type: OTHER
Group type: OTHER
Intervention: 75%VO2max TBR100
Description: Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
Study: NCT00123838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calypso® 4D Localization System
Description: Localization of prostate irradiation.
Study: NCT03627663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectic Behavior Therapy - Skills System
Description: Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
Study: NCT00819676

Intervention type: OTHER
Intervention: analysis of exhaled breath by biosensors

Intervention type: OTHER
Intervention: analysis of exhaled breath by biosensors

Intervention type: OTHER
Intervention: measurement of exhaled nitric oxide

Intervention type: OTHER
Intervention: measurement of exhaled nitric oxide
Study: NCT03967119

Intervention type: DEVICE
Intervention: Patient monitoring
Description: Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/\[(PWmax+PWmin)/2\].
Study: NCT02651961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exchange of total hip or knee arthroplasty on same time
Description: Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
Study: NCT02825628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: formulation: solution for infusion route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: formulation: solution for infusion route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: formulation: solution for infusion route of administration: intravenous infusion
Study: NCT02064816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
Study: NCT03911726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single PET/MR-measurement
Description: A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.

Intervention type: RADIATION
Group type: OTHER
Intervention: Single PET/MR-measurement
Description: A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single PET/MR-measurement
Description: A single PET/MR-measurement using \[18F\]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
Study: NCT01155934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone Orally Disintegrating Tablets
Description: Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Orally Disintegrating Tablets
Description: Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
Study: NCT01251419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Proximity and Conversion to Generic Medications
Description: At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Proximity and Conversion to Generic Medications
Description: At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Proximity and Conversion to Generic Medications
Description: At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
Study: NCT03787784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI presentation
Description: Automatic diagnosis information of AI is visible to endoscopist
Study: NCT01265108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose.
Description: Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
Study: NCT04440215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation and team meetings and team care plans
Description: A mix of home or rehabilitation center visits and telerehabilitation will be planned by the rehabilitation team for a maximum of 16 weeks. Moreover, for each participant enrolled, a multidisciplinary meeting will be organised. The patient/family will participate in the meeting and the decision making process using the telerehabilitation platform. The team will generate an interprofessional individualized treatment plan, aiming for an interprofessional shared decision making process.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Rehabilitation teams will be instructed to provide care as they have been doing previously. Currently, this translates into no telerehabilitation, and interdisciplinary meetings not systematically organized and/or not involving a complete team of professionals.
Study: NCT01776437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: 500mcg dose of BMN 673, 2 discrete single doses separated by 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: 500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
Study: NCT02874625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental restoration
Description: Teeth with caries will be restored

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental restoration
Description: Teeth with caries will be restored
Study: NCT02754804

Intervention type: DEVICE
Intervention: Biomechanic parameters
Description: recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
Study: NCT01703260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast dose
Study: NCT01277965

Intervention type: OTHER
Group type: OTHER
Intervention: Rest
Description: Patient will be in rest, basal insulin flow rate will not be change
Study: NCT02091726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicirc instrument plus cyanoacrylate tissue adhesive
Description: Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
Study: NCT02388724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Placebo
Description: Vonoprazan placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules
Study: NCT04376021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babywearing
Description: Increase mother-infant physical contact through babywearing